HALO·Halozyme Therapeutics Inc.
HALO|Analyst Targets
HALO|Insider Trading
HALO|Fundamentals
HALO|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.29 | - | - |
| Q3'25 | $1.63 | $1.72 | +5.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $499M | - | - |
| Q3'25 | - | $354M | - |
HALO|Monthly Returns
Market Data
HALO Stock Snapshot
- Market cap
- 12.29B
- P/E ratio
- 29.7
- Day range
- $109.68 – $113.99
- News sentiment
- 82/100 · Bullish
- Analyst target
- $99.56 (-10.1%)
- Consensus
- Buy · 18 analysts
Price is near its 52-week high, and the momentum read backs that positioning up. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.
Reverse DCF
What growth is priced into HALO?
At today's price, Halozyme Therapeutics Inc. needs to grow free cash flow about 10.7% a year for the next 10 years to justify its valuation at a 8.62% cost of capital. Over its actual history it has compounded free cash flow at 27.6% a year, so the market is asking for 16.9 percentage points below its own delivered rate. On that basis HALO looks priced below what its own growth record supports.
- Implied FCF growth
- 10.7%
- Historical FCF CAGR
- 27.6%
- Growth gap
- -16.9 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 8.62%
- Beta
- 0.80
Behaviour On Record
What HALO's own history says about today's numbers
- Realized volatility (21d)
- 28.4% 12th pct
- Below its peak
- -6.4%
- vs 200-day average
- +38.2%
- Up days (1y)
- 48%
Halozyme Therapeutics Inc. is currently running 28.4% annualised volatility over the last 21 sessions. Measured against HALO's own 13 years of daily returns rather than a market-wide average, that is the 12th percentile — unusually subdued by its own history, against a typical reading of 42.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
HALO is trading -6.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -35.5%, and the deepest was -60.0% in 2014. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +38.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 91st percentile — a wider gap than this stock usually carries. Over the past year HALO closed higher on 48% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, HALO finished the month higher 6 of 13 times, with a median return of +0.0% and an average of -2.3%. Its strongest month historically has been November at +10.6% on average, its weakest March at -3.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: HALO has opened more than 2% away from the prior close in 385 of 3,267 sessions (11.8% of the time), with the largest gaps running +16.7% and -11.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against HALO's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of HALO's sector?
Halozyme Therapeutics Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, HALO ranks 10th of 15 tracked industries, lagging.
- Sector rank
- #3 of 12
- Sector state
- Lagging
- Sector rotation score
- 64
- Industry rank
- #10 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on HALO?
HC Wainwright & Co. most recently reiterated its rating on Halozyme Therapeutics Inc. to Buy on Sep 2, 2026 with a price target of $115. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- HC Wainwright & Co. — Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Held by These ETFs
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Citadel Advisors LLC | • Hold | 78,380,490 | 70.64% | $143.12M | 2026-09-02 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2026-03-09 | 2026-04-07 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-03-24 | 2025-04-07 |
| Mark Warner | Senate | VA | ▼ Sell | $500K - $1.0M | 2017-11-06 | 2017-12-08 |